AZUSA, CA -- (MARKET WIRE) -- 06/19/2006 -- Viral Genetics, Inc. (OTCBB: VRAL) (“VGI” or the “Company”) is pleased to announce the results of its 137-patient “TNP-001" clinical trial of VGV-1(also referred to as “thymus nuclear protein” or “TNP”), conducted in South Africa in concert with Viral Genetics South Africa (Pty) Ltd (“VGSA”). Results were consistent with the Company’s four prior prospective clinical studies of VGV-1, confirming immunological bioactivity and antiviral properties while also suggesting that the optimal dose has not yet been identified and requires further study. Specifically, the results indicate that a proportion of patients receiving eight weeks of treatment with VGV-1 and no additional anti-HIV therapy experienced a decrease in viral load (measured by Polymerase Chain Reaction or “PCR”) at day 150 that diminished at day 240. Additionally, in aggregate, VGV-1 treated patients demonstrated positive changes in immune markers associated with HIV infection and proviral peripheral blood mononuclear cells (“PBMCs”). Proviral PBMCs are cells that have been infected with HIV and produce additional copies of the virus.
